MA39048B1 - Nouveaux inhibiteurs de la dgat2 - Google Patents

Nouveaux inhibiteurs de la dgat2

Info

Publication number
MA39048B1
MA39048B1 MA39048A MA39048A MA39048B1 MA 39048 B1 MA39048 B1 MA 39048B1 MA 39048 A MA39048 A MA 39048A MA 39048 A MA39048 A MA 39048A MA 39048 B1 MA39048 B1 MA 39048B1
Authority
MA
Morocco
Prior art keywords
dgat2
new inhibitors
compounds
methods
inhibitors
Prior art date
Application number
MA39048A
Other languages
English (en)
Other versions
MA39048A1 (fr
Inventor
Nicholas Paul Camp
Manisha Naik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39048(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39048A1 publication Critical patent/MA39048A1/fr
Publication of MA39048B1 publication Critical patent/MA39048B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne des composés de la formule ci-dessous : (i) où r désigne h ou -ch3; des méthodes pour traiter des patients atteints d'hypertriglycéridémie et de maladies cardiovasculaires, y compris la dyslipidémie et l'athérosclérose, ainsi que des procédés pour préparer lesdits composés.
MA39048A 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2 MA39048B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908339P 2013-11-25 2013-11-25
PCT/US2014/066339 WO2015077299A1 (fr) 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2

Publications (2)

Publication Number Publication Date
MA39048A1 MA39048A1 (fr) 2017-05-31
MA39048B1 true MA39048B1 (fr) 2018-04-30

Family

ID=52016867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39048A MA39048B1 (fr) 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2

Country Status (24)

Country Link
US (1) US9073901B2 (fr)
EP (1) EP3074381B1 (fr)
JP (1) JP6155395B2 (fr)
KR (1) KR20160072252A (fr)
CN (1) CN105764889B (fr)
AP (1) AP2016009230A0 (fr)
AR (1) AR098394A1 (fr)
AU (1) AU2014353109B2 (fr)
CA (1) CA2928468A1 (fr)
CL (1) CL2016001172A1 (fr)
CR (1) CR20160216A (fr)
DO (1) DOP2016000120A (fr)
EA (1) EA201690847A1 (fr)
ES (1) ES2695302T3 (fr)
HK (1) HK1223367A1 (fr)
IL (1) IL245245A0 (fr)
MA (1) MA39048B1 (fr)
MX (1) MX2016006665A (fr)
NZ (1) NZ719444A (fr)
PE (1) PE20161099A1 (fr)
PH (1) PH12016500963A1 (fr)
TN (1) TN2016000146A1 (fr)
TW (1) TW201609668A (fr)
WO (1) WO2015077299A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982267C (fr) * 2015-05-20 2019-11-12 Eli Lilly And Company Nouveaux inhibiteurs de la dgat2
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
EP4153584A1 (fr) 2020-05-18 2023-03-29 Merck Sharp & Dohme LLC Nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
TW202229243A (zh) 2020-10-08 2022-08-01 美商默沙東藥廠 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備
CA3198344A1 (fr) 2020-11-20 2022-05-27 Patrick T. GUNNING Procedes et composition pour effectuer des modifications de kras
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170691A1 (en) 2001-12-19 2003-09-11 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
AU2003253925A1 (en) 2002-07-18 2004-02-09 Banyu Pharmaceutical Co., Ltd. Combination therapy for the treatment of obesity
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
CN1997640A (zh) * 2004-06-04 2007-07-11 艾尼纳制药公司 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗
EP1807102A2 (fr) 2004-10-29 2007-07-18 Merck & Co., Inc. Compositions et procedes de traitement de l'obesite et du dysfonctionnement sexuel
WO2008129080A1 (fr) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs de protéine kinases
WO2011078102A1 (fr) * 2009-12-22 2011-06-30 第一三共株式会社 Nouveau dérivé de phénoxypyrimidine
WO2011087857A2 (fr) 2009-12-22 2011-07-21 The Administrators Of The Tulane Educational Fund Compositions et procédés de traitement de l'obésité et du diabète
JP5921525B2 (ja) * 2010-03-22 2016-05-24 リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬的に活性のある二置換のトリアジン誘導体
WO2012118563A2 (fr) * 2011-03-03 2012-09-07 Vanderbilt University Analogues de 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide en tant que modulateurs allostériques négatifs de mglur5 et procédé pour les préparer et les utiliser
EP2561867A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Inhibiteurs de CDK9 pour le traitement du carcinome de la ligne médiane
EP2562265A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Sensibilité à des inhibiteurs sélectifs de CDK9
EP2834238B1 (fr) * 2012-04-06 2017-02-01 Pfizer Inc. Inhibiteurs de diacylglycérol acyltransférase 2

Also Published As

Publication number Publication date
JP2016539115A (ja) 2016-12-15
AR098394A1 (es) 2016-05-26
WO2015077299A1 (fr) 2015-05-28
CN105764889A (zh) 2016-07-13
IL245245A0 (en) 2016-06-30
DOP2016000120A (es) 2016-06-15
PH12016500963A1 (en) 2016-06-20
ES2695302T3 (es) 2019-01-03
CL2016001172A1 (es) 2016-12-09
AP2016009230A0 (en) 2016-05-31
MA39048A1 (fr) 2017-05-31
NZ719444A (en) 2017-12-22
CA2928468A1 (fr) 2015-05-28
HK1223367A1 (zh) 2017-07-28
AU2014353109A1 (en) 2016-05-12
TW201609668A (zh) 2016-03-16
CR20160216A (es) 2016-06-27
EP3074381A1 (fr) 2016-10-05
PE20161099A1 (es) 2016-10-22
US9073901B2 (en) 2015-07-07
MX2016006665A (es) 2016-07-26
KR20160072252A (ko) 2016-06-22
US20150148358A1 (en) 2015-05-28
JP6155395B2 (ja) 2017-06-28
TN2016000146A1 (en) 2017-10-06
EP3074381B1 (fr) 2018-07-04
EA201690847A1 (ru) 2016-09-30
CN105764889B (zh) 2018-01-02
AU2014353109B2 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
MA40301A1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
EA201391290A1 (ru) Гетероциклические модуляторы синтеза липидов
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
MA40895A (fr) Synthèse de copanlisib et son sel de dichlorhydrate
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
EA201690844A1 (ru) Ингибиторы gsk-3
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
IN2012DN00695A (fr)
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EA201792187A1 (ru) Производные азахиназолин карбоксамида
EA201170074A1 (ru) Изохинолиноновые производные в качестве антагонистов nk3
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
JO3248B1 (ar) عملية لتحضير إنزيمات مثبطة من نوع c-fms
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения
JO3185B1 (ar) طريقة لتحضير مشتقات استر متغايرة الحلقة
MA39756A (fr) Nouveau sel de l'ivabradine et son procédé de préparation
IN2013MU01256A (fr)
EA201300141A1 (ru) Алкилзамещенные 3-гидроксипиридины для лечения депрессии